Indoco Remedies Limited has officially announced its audited financial results for the quarter and financial year concluded March 31, 2026. During a board meeting held on May 7, 2026, the company’s directors also recommended a final dividend of Rs. 0.20 per equity share, which represents 10% of the face value of Rs. 2/- each, subject to upcoming shareholder approval at the 79th Annual General Meeting.

For the fourth quarter of the 2025-26 financial year, the company’s consolidated revenue from operations reached Rs. 455.90 Crores, demonstrating a growth of 4.96% from the Rs. 434.34 Crores reported in the preceding third quarter. When compared to the corresponding quarter of the previous year (March 31, 2025), which saw revenues of Rs. 383.89 Crores, the current performance reflects a significant year-on-year increase of 18.76%. In terms of profitability, the company reported a consolidated net loss of Rs. 23.68 Crores for the quarter ended March 31, 2026. This figure shows a sequential improvement from the net loss of Rs. 29.45 Crores recorded in the quarter ended December 31, 2025. Furthermore, the current quarter’s results indicate a narrowed loss compared to the Rs. 41.34 Crores loss posted in the same quarter of the previous financial year.

Indoco Remedies Limited is a fully integrated, research-oriented pharmaceutical organization headquartered in Mumbai, India. The company possesses a robust international presence and operates through ten manufacturing facilities—six dedicated to Finished Dosage Forms (FDFs) and four for Active Pharmaceutical Ingredients (APIs). Supported by a state-of-the-art R&D center, Indoco’s facilities have earned approvals from major global regulatory bodies, including the USFDA and UK-MHRA. The firm manages a diverse therapeutic portfolio covering segments such as Gastro-intestinal, Respiratory, Anti-Infectives, and Stomatologicals, generating over 100 million prescriptions annually. Notable brands in its portfolio include Cyclopam, Febrex Plus, and Sensodent-K. As of 2025, the company continues to expand its global reach through strategic tie-ups with large generic firms worldwide.